LLY - Innovent Biologics Xuanzhu collaborate on clinical trial for advanced solid tumors in China
2023-12-28 04:13:45 ET
More on Innovent Biologics:
- Innovent marks China's first regulatory review of a KRAS G12C inhibitor
- Historical earnings data for Innovent Biologics
- Financial information for Innovent Biologics
For further details see:
Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China